Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP167380.RA79q8OFlJvyZk4Yjxwt-MH0vwrX9qnz3U3EjMZTQplxs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP167380.RA79q8OFlJvyZk4Yjxwt-MH0vwrX9qnz3U3EjMZTQplxs130_assertion type Assertion NP167380.RA79q8OFlJvyZk4Yjxwt-MH0vwrX9qnz3U3EjMZTQplxs130_head.
- NP167380.RA79q8OFlJvyZk4Yjxwt-MH0vwrX9qnz3U3EjMZTQplxs130_assertion wasGeneratedBy ECO_0000203 NP167380.RA79q8OFlJvyZk4Yjxwt-MH0vwrX9qnz3U3EjMZTQplxs130_provenance.
- NP167380.RA79q8OFlJvyZk4Yjxwt-MH0vwrX9qnz3U3EjMZTQplxs130_assertion wasDerivedFrom befree-20140225 NP167380.RA79q8OFlJvyZk4Yjxwt-MH0vwrX9qnz3U3EjMZTQplxs130_provenance.
- NP167380.RA79q8OFlJvyZk4Yjxwt-MH0vwrX9qnz3U3EjMZTQplxs130_assertion SIO_000772 12646934 NP167380.RA79q8OFlJvyZk4Yjxwt-MH0vwrX9qnz3U3EjMZTQplxs130_provenance.
- NP167380.RA79q8OFlJvyZk4Yjxwt-MH0vwrX9qnz3U3EjMZTQplxs130_assertion evidence source_evidence_literature NP167380.RA79q8OFlJvyZk4Yjxwt-MH0vwrX9qnz3U3EjMZTQplxs130_provenance.
- NP167380.RA79q8OFlJvyZk4Yjxwt-MH0vwrX9qnz3U3EjMZTQplxs130_assertion description "[The median duration of imatinib treatment before the identification of cytogenetic abnormalities in BCR-ABL-negative cells was 13 months.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP167380.RA79q8OFlJvyZk4Yjxwt-MH0vwrX9qnz3U3EjMZTQplxs130_provenance.